Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine

Thomas P.C. Dorlo, Manica Balasegaram, María Angeles Lima, Peter J. De Vries, Jos H. Beijnen, Alwin D.R. Huitema

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)

Abstract

Objectives: Use of miltefosine in the treatment of visceral leishmaniasis (VL) is hampered by its potential teratogenicity. The duration of adequate contraceptive cover in females of child-bearing potential after cessation of a potentially teratogenic drug therapy remains debated. The objective of this study was to provide a rational approach to suggest durations of contraceptive cover for various miltefosine regimens. Methods: A human reproductive safety threshold exposure limit was derived using animal-to-human dose conversion. Pharmacokinetic (PK) data for miltefosine in females are lacking; a previously developed population PK model and a comprehensive anthropometric dataset were used to simulate PK data for Indian female VL patients receiving miltefosine for 5, 7, 10 or 28 days. Probability of supra-threshold miltefosine exposure was used to evaluate adequate durations of post-treatment contraceptive cover for the various regimens. Results: PK data were simulated for 465 treated Indian female VL patients of child-bearing potential with a median age of 25 years (IQR 16-31 years) and median weight of 38 kg (IQR 34-42 kg). From animal reproductive toxicity studies, a human reproductive safety threshold exposure limit was derived of 24.5 μg · day/mL. Probability of 'unprotected' supra-threshold miltefosine exposure was very low (<0.2%) for a post-treatment contraceptive cover period of 4 months for the standard 28 day regimen, and of 2 months for the shorter regimens. Conclusions: To our knowledge, this is the first study providing rational suggestions for contraceptive cover for a teratogenic drug based on animal-to-human dose conversion. For the 28 day miltefosine regimen, post-treatment contraceptive cover may be extended to 4 months, whereas for all shorter regimens 2 months may be adequate.

Original languageEnglish
Article numberdks164
Pages (from-to)1996-2004
Number of pages9
JournalJournal of Antimicrobial Chemotherapy
Volume67
Issue number8
DOIs
Publication statusPublished - Aug 2012
Externally publishedYes

Keywords

  • Anticonceptive
  • Contraception
  • Leishmaniasis
  • Monte Carlo simulation
  • Pharmacokinetics
  • Pharmacometrics
  • Population pharmacokinetics
  • Reproductive health
  • Reproductive toxicity
  • Teratogenicity
  • Translational research
  • Visceral leishmaniasis

Fingerprint

Dive into the research topics of 'Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine'. Together they form a unique fingerprint.

Cite this